1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/23225
Full metadata record
DC FieldValueLanguage
dc.contributor.authorEconomopoulos, T.en
dc.contributor.authorPsyrri, A.en
dc.contributor.authorDimopoulos, M. A.en
dc.contributor.authorKalogera-Fountzila, A.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorTsatalas, C.en
dc.contributor.authorNikolaides, C.en
dc.contributor.authorMellou, S.en
dc.contributor.authorXiros, N.en
dc.contributor.authorFountzilas, G.en
dc.date.accessioned2015-11-24T19:31:12Z-
dc.date.available2015-11-24T19:31:12Z-
dc.identifier.issn1528-9117-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23225-
dc.rightsDefault Licence-
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAntibodies, Monoclonal/administration & dosageen
dc.subjectAntibodies, Monoclonal, Murine-Deriveden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic useen
dc.subjectCyclophosphamide/adverse effects/therapeutic useen
dc.subjectEpirubicin/adverse effects/therapeutic useen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectLymphoma, B-Cell/drug therapy/pathologyen
dc.subjectLymphoma, Mantle-Cell/drug therapy/pathologyen
dc.subjectLymphoma, Non-Hodgkin/*drug therapy/pathologyen
dc.subjectLymphoma, T-Cell/drug therapy/pathologyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPrednisone/adverse effects/therapeutic useen
dc.subjectVincristine/adverse effects/therapeutic useen
dc.titleCEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: results of the HE22A99 trial of the Hellenic Cooperative Oncology Groupen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1097/PPO.0b013e3181570170-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/17921732-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2007-
heal.abstractBACKGROUND: In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) improves outcomes in patients with previously untreated aggressive lymphomas. In a secondary analysis we evaluated the impact of adding rituximab to CEOP-14/CEOP-21 chemotherapy. STUDY DESIGN: The trial opened in March 1999, and patients were randomly assigned to either CEOP-14 or CEOP-21. All patients enrolled from May 2002 onward received rituximab with each chemotherapy cycle, and those attaining a complete response received rituximab consolidation. RESULTS: Complete and overall response rates in the CEOP-21 +/- rituximab (N = 114) and CEOP-14 +/- rituximab (N = 103) arms were similar, as were the overall survival (P = 0.769) and time to progression distributions (P = 0.969). Rituximab was shown to have a beneficial effect both on the overall survival and on the time to progression. CONCLUSIONS: Thus far, no significant improvement in outcome has been demonstrated with CEOP-14 +/- rituximab versus CEOP-21 +/- rituximab. However, with addition of rituximab to CEOP-21/CEOP-14, significant improvements in time to progression and overall survival were achieved.en
heal.journalNameCancer Jen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
There are no files associated with this item.
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons